BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38455525)

  • 1. Pro-tumorigenic activity of PYCR1 in gastric cancer through regulating the PI3K/AKT signaling.
    Xiao H; Huang J; Wu H; Li Y; Wang Y
    Heliyon; 2024 Mar; 10(5):e26883. PubMed ID: 38455525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrroline-5-carboxylate reductase 1 (PYCR1) upregulation contributes to gastric cancer progression and indicates poor survival outcome.
    Xiao S; Li S; Yuan Z; Zhou L
    Ann Transl Med; 2020 Aug; 8(15):937. PubMed ID: 32953737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PYCR1, BANF1, and STARD8 Expression in Gastric Carcinoma: A Clinicopathologic, Prognostic, and Immunohistochemical Study.
    Harb OA; Elfeky MA; Alabiad MA; Hemeda R; Allam AS; El Hawary AT; Elbaz M; Sharaf AL; Gertallah LM; Abdelaziz AM; Shalaby AM; Alorini M; Yahia AIO; Negm M
    Appl Immunohistochem Mol Morphol; 2024 Feb; 32(2):102-110. PubMed ID: 37982568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells.
    Zhang J; Shang L; Jiang W; Wu W
    Bioengineered; 2022 Mar; 13(3):7904-7918. PubMed ID: 35293266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PYCR1 promotes bladder cancer by affecting the Akt/Wnt/β-catenin signaling.
    Du S; Sui Y; Ren W; Zhou J; Du C
    J Bioenerg Biomembr; 2021 Apr; 53(2):247-258. PubMed ID: 33689096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PYCR1 is Associated with Papillary Renal Cell Carcinoma Progression.
    Wang QL; Liu L
    Open Med (Wars); 2019; 14():586-592. PubMed ID: 31428683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrroline-5-Carboxylate Reductase 1 Accelerates the Migration and Invasion of Nonsmall Cell Lung Cancer
    Sang S; Zhang C; Shan J
    Cancer Biother Radiopharm; 2019 Aug; 34(6):380-387. PubMed ID: 30916574
    [No Abstract]   [Full Text] [Related]  

  • 8. Knockdown of PYCR1 suppressed the malignant phenotype of human hepatocellular carcinoma cells via inhibiting the AKT pathway activation.
    Guo J; Cheng X; Tian Y; Li B; Zhang X; Gao X; An Y
    Reprod Biol; 2021 Sep; 21(3):100534. PubMed ID: 34271243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrroline-5-carboxylate reductase 1 promotes cell proliferation via inhibiting apoptosis in human malignant melanoma.
    Ye Y; Wu Y; Wang J
    Cancer Manag Res; 2018; 10():6399-6407. PubMed ID: 30568501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modification facilitates proline synthase PYCR1 aberrant expression in gastric cancer.
    Xiao S; Yao X; Ye J; Tian X; Yin Z; Zhou L
    Biochim Biophys Acta Gene Regul Mech; 2022 Aug; 1865(6):194829. PubMed ID: 35654390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer.
    Zhuang J; Song Y; Ye Y; He S; Ma X; Zhang M; Ni J; Wang J; Xia W
    J Transl Med; 2019 Oct; 17(1):343. PubMed ID: 31619254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [FJX1 overexpression is associated with poor prognosis and promotes gastric cancer proliferation
    Zhang H; Zhang Z; Wang Q; Wang L; Yang Z; Geng Z; Wang Y; Li J; Zuo L
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jun; 43(6):975-984. PubMed ID: 37439170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signaling pathway in lung adenocarcinoma.
    Gao Y; Luo L; Xie Y; Zhao Y; Yao J; Liu X
    Mol Carcinog; 2020 May; 59(5):503-511. PubMed ID: 32133692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrroline-5-carboxylate reductase 1 promotes proliferation and inhibits apoptosis in non-small cell lung cancer.
    Cai F; Miao Y; Liu C; Wu T; Shen S; Su X; Shi Y
    Oncol Lett; 2018 Jan; 15(1):731-740. PubMed ID: 29403556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DLEU2 silencing impedes the migration, invasion and EMT in gastric cancer cell by suppressing PI3K/AKT signaling pathway.
    Hu J; Wang M; Yang Y; Xing Y; Li S
    Immunopharmacol Immunotoxicol; 2022 Oct; 44(5):719-731. PubMed ID: 35736813
    [No Abstract]   [Full Text] [Related]  

  • 16. Vernodalin Suppresses Tumor Proliferation and Increases Apoptosis of Gastric Cancer Cells Through Attenuation of FAK/PI3K/AKT/mTOR and MAPKs Signaling Pathways.
    Luo Y; Zhang D; Hou L; Lin N
    Curr Pharm Biotechnol; 2023; 24(5):708-717. PubMed ID: 35909270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer.
    Chu XD; Lin ZB; Huang T; Ding H; Zhang YR; Zhao Z; Huangfu SC; Qiu SH; Guo YG; Chu XL; Pan JH; Pan YL
    BMC Cancer; 2022 Mar; 22(1):250. PubMed ID: 35255858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway.
    Li Z; Jiang Y; Liu J; Fu H; Yang Q; Song W; Li Y
    Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37293856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZNF143 enhances metastasis of gastric cancer by promoting the process of EMT through PI3K/AKT signaling pathway.
    Wei S; Wang L; Zhang L; Li B; Li Z; Zhang Q; Wang J; Chen L; Sun G; Li Q; Xu H; Zhang D; Xu Z
    Tumour Biol; 2016 Sep; 37(9):12813-12821. PubMed ID: 27449034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma.
    Wang H; Mao W; Lou W; Jin D; Wu W; Wang D; Kuang T; Rong Y; Xu X; Zhang L
    J Cancer; 2022; 13(5):1501-1511. PubMed ID: 35371311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.